The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Mechanisms of action of CD38 antibodies in myeloma
Niels van de Donk, MD, PhD, VU University Medical Center, Amsterdam, Netherlands, discusses the mechanisms of action of CD38 antibodies in multiple myeloma. CD38 antibodies are thought to exert their anti-cancer activity through numerous modes of action, including the induction of NK-cell mediated antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) by monocytes, as well as immune suppressor cell eradication. Prof. van de Donk comments on recent findings suggesting that NK-cell characteristics may be predictive of responses to CD83-targeted agents and how these insights may be able to improve treatment efficacy. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
